GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (STU:37Z) » Definitions » Research & Development

Allakos (STU:37Z) Research & Development : €140.99 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Allakos Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Allakos's Research & Development for the three months ended in Mar. 2024 was €32.04 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €140.99 Mil.

Allakos Research & Development Historical Data

The historical data trend for Allakos's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allakos Research & Development Chart

Allakos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial 55.67 86.75 173.75 250.24 138.38

Allakos Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.90 25.18 34.43 49.34 32.04

Allakos Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €140.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allakos  (STU:37Z) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Allakos Research & Development Related Terms

Thank you for viewing the detailed overview of Allakos's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Allakos (STU:37Z) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (STU:37Z) » Definitions » Research & Development
Comparable Companies
AKBA STOK APLT VSTM ZVRA STRO GLUE IKNA OBIO QSI OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ALLK:USA
Address
825 Industrial Road, Suite 500, San Carlos, CA, USA, 94070
Website
https://www.allakos.com
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.

Allakos (STU:37Z) Headlines

No Headlines